RESEARCH & DEVELOPMENT
OVERVIEW
Vyera's research and development resources are devoted to identifying next-generation therapies for toxoplasmosis and other neglected parasitic infections – diseases with limited treatment options.
In Q1 of 2018, Vyera hopes to begin its first clinical trial to investigate the safety of TUR-006, a new molecule discovered and developed internally, for the treatment of toxoplasmosis.
Our Pipeline
Our pipeline is advancing with the support of a global team dedicated to exploring new ways to address disease.